The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Hims & Hers reports Q1 results. See how financial growth and regulatory shifts affect patient access to semaglutide, tirzepatide, and peptide therapy.
The quest for physical perfection is driving a new trend among teen boys and young men: the use of unapproved peptides. This article delves into the motivations, the substances involved, and the significant health concerns surrounding this practice.
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
Comedian Greg Davies reveals the physical and psychological effects of stopping Ozempic after significant weight loss, offering insights for patients on peptide therapy.
With healthcare costs projected to jump another 9% next year, driven significantly by GLP-1 medications like semaglutide and tirzepatide, employers face unprecedented budget pressure. This article explores why reactive cost-cutting fails and how investing upstream in robust primary care coordination is the key to sustainable financial health and better patient outcomes.
Navigating weight loss with GLP-1 medications such as semaglutide and tirzepatide requires careful attention to lifestyle choices. This guide details 8 crucial things to avoid to ensure you experience the full benefits and fewer side effects.
Once primarily a diabetes medication, Ozempic and other GLP-1 agonists have experienced an unprecedented rise in popularity, driven by their significant impact on weight loss. This article delves into the data, the science, and the cultural context behind this revolution.
GLP-1 agonists are revolutionizing weight management, but their rise has coincided with a surge in online wellness culture, leading to a 'wild west' of unregulated peptide use. This article delves into the science, societal impact, and potential dangers.
